Publication:
Is It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5%

Simple item page
dc.contributor.authorsReid, Michelle; Balci, Serdar; Bagci, Pelin; Saka, Burcu; Pehlivanoglu, Burcin; Seven, Ipek Erbarut; Basturk, Olca; Adsay, N. Volkan
dc.date.accessioned2022-03-12T16:24:43Z
dc.date.accessioned2026-01-11T06:21:25Z
dc.date.available2022-03-12T16:24:43Z
dc.date.issued2020
dc.identifier.doidoiWOS:000518328803465
dc.identifier.eissn1530-0307
dc.identifier.issn0023-6837
dc.identifier.urihttps://hdl.handle.net/11424/226435
dc.identifier.wosWOS:000518328803465
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.relation.ispartofLABORATORY INVESTIGATION
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleIs It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5%
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage1673
oaire.citation.issueSUPPL 1
oaire.citation.startPage1673
oaire.citation.titleLABORATORY INVESTIGATION
oaire.citation.volume100

Files

Collections

Araştırma Çıktıları